Hemasphere

Papers
(The TQCC of Hemasphere is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
P880: EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A SUBGROUP ANALYSIS FROM MAGNETISMM-3183
S182: ORAL IPTACOPAN MONOTHERAPY INCREASES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE VIA CONTROL OF INTRA- AND EXTRAVASCULAR HEMOLYSIS IN ANTI-C5-TREATED PNH PATIENTS WITH AN121
P07: RESULTS FROM THE CC-220-MM-001 DOSE-EXPANSION PHASE OF IBERDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA78
S233: AXICABTAGENE CILOLEUCEL AS SECOND-LINE THERAPY FOR LARGE B-CELL LYMPHOMA IN TRANSPLANT-INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY65
P1462: POPULATION-BASED REAL WORLD RESULTS OF CD19-DIRECTED CAR T-CELL THERAPY FOR PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: A DUTCH CAR T-CELL TUMORBOARD EXPERIENCE63
PB2064: THE COMPLETE STUDY: A SINGLE ARM, MULTICENTER OBSERVATIONAL STUDY TO EVALUATE EFFECTIVENESS OF PEGCETACOPLAN UNDER REAL WORLD CONDITIONS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (P60
P1044: REDUCTION IN RED BLOOD CELL TRANSFUSION BURDEN: A NOVEL LONGITUDINAL TIME-DEPENDENT ANALYSIS IN PATIENTS WITH TRANSFUSION-DEPENDENT MYELOFIBROSIS TREATED WITH MOMELOTINIB55
PB1708: CHARACTERIZATION OF GLOBAL CYTOGENOMICS FEATURES IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA BY OPTICAL GENOME MAPPING51
P363: A PHASE II STUDY OF FLUMATINIB WITH CHEMOTHERAPY FOR NEWLY DIAGNOSED PH/BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS: UPDATED RESULTS FROM RJ-ALL2020.2A TRIAL40
P760: PATTERNS OF HYPOMETHYLATING AGENT FAILURE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES39
IDALLO study: A retrospective multicenter study of the SFGM‐TC evaluating the efficacy and safety of ivosidenib in relapsed IDH1‐mutated AML after allogeneic hematopoietic cell transplantation38
When to stop: Transfusions, difficult conversations and creativity36
Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study35
Preclinical evaluation of the CD38‐targeting engineered toxin body MT‐0169 against multiple myeloma34
Serologic Responses to COVID-19 Vaccines in Hematological Patients Are Predominantly Impaired in Lymphoid but not in Myeloid Malignancies34
P1489: HIGH DOSE IRON IMPAIRS MALIGNANT B-CELL VIABILITY AND IMPROVES IMMUNE ANTITUMOR FUNCTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA34
P401: INNOVATIVE REDUCED-DOSE CHEMOTHERAPY FOLLOWED BY BLINATUMOMAB INDUCTION THERAPY FOR SUCCESSFUL MANAGEMENT OF TREATMENT NAIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ADULTS: A MULTICENTER, REAL-WORLD33
PB2391: FREQUENCY OF IKZF3 MUTATION IN WALDENSTRÖM’S MACROGLOBULINEMIA31
P1582: CLINICAL CHARACTERISTICS AND INFECTION-RELATED OUTCOMES IN PATIENTS WITH LYMPHOID MALIGNANCIES WITH OR WITHOUT SECONDARY IMMUNODEFICIENCIES: RESULTS FROM A RETROSPECTIVE MULTI-DATABASE STUDY31
P011: IPS-7 or IPS-3 to identify very-high risk patients in advanced Classical Hodgkin’s Lymphoma: Which score to choose31
PB2091: INFLUENCE OF HISTOLOGICAL GRADE IN CLINICAL CHARACTERISTICS AND LONG-TERM OUTCOME OF FOLICULAR LYMPHOMA26
PB2044: TRIAL IN PROGRESS: OBSERVATIONAL STUDY IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED IN ITALY WITH MIDOSTAURIN (OVIDIO)25
P1248: CTP SYNTHASE 1 IS A NOVEL TARGET IN T CELL CANCERS, WITH SMALL MOLECULE INHIBITION INDUCING DEATH OF NEOPLASTIC HUMAN T CELLS IN VITRO AND INHIBITION OF THEIR GROWTH IN AN IN VIVO XENOTRANSPLAN25
PB2088: IMMUNE PROFILE OF PATIENTS WITH FOLLICULAR LYMPHOMA ASSESSED BY FLOW CYTOMETRY IN PERIPHERAL BLOOD: CHARACTERISTICS AT DIAGNOSIS AND AT RELAPSE OF THE DISEASE25
P1254: RESPONSE TO DA-EPOCH-R IN PATIENTS WITH HIGH GRADE B CELL LYMPHOMA IS ASSOCIATED WITH A REDUCTION OF PD1 POSITIVE EXHAUSTED CD8 T CELLS23
P1685: CHEMOTHERAPY-INDUCED ENDOTHELIAL DAMAGE AS UNDERLYING CAUSE FOR PERIPHERAL NEUROPATHY AND REDUCED METABOLISM IN STATIC PRESSURE-ADJUSTED COMPRESSION FOR CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPAT23
PB2176: AN AUSTRALIAN/NEW ZEALAND RANDOMIZED TRIAL OF POST-TRANSPLANT CYCLOPHOSPHAMIDE IN MATCHED RELATED PERIPHERAL BLOOD STEM CELL TRANSPLANTS FOR ACUTE LEUKAEMIA OR MYELODYSPLASIA – ALLG BM1223
PB2256: BACTERIAL BLOODSTREAM INFECTIONS AND ANTIMICROBIAL SUSCEPTIBILITY PATTERN IN PATIENTS WITH ACUTE LEUCAEMIA23
PB2107: CLINICAL MANIFESTATIONS AND EFFICACY ANALYSIS OF 71 CASES OF AIDS-RELATED LYMPHOMA22
P1586: IN-HOSPITAL MORTALITY AND POOR PROGNOSIS FACTORS ASSESSMENT IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND COVID-19.22
PB2274: A PROGNOSTIC MODEL TO PREDICT MORTALITY IN ICU DEPARTMENT OF HEMATOLOGY CLINIC22
P616: THE LOSS OF IΚBΕ INHIBITOR ACCELERATES DISEASE DEVELOPMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA21
P050: Reed-Sternberg cells accelerate glycolytic and mitochondrial metabolism of tumor microenvironment cells21
T084: Treatment patterns and outcomes for Hodgkin’s Lymphoma (HL) patients (pts) aged 60 and older: a report from the Brazilian Prospective Hodgkin’s lymphoma Registry20
P1608: EXPERIENCE AND COMPLICATIONS WITH THE USE OF PICCS IN HEMATOLOGIC PATIENTS20
PB1982: DEEPENING OF RESPONSE IN PATIENTS WITH MULTIPLE MYELOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION: A MULTICENTRIC STUDY IN A LATINO POPULATION20
P1129: ACALABRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): RESULTS OF A PHASE 2, MULTICENTER, OPEN-LABEL TRIAL19
P500: A REAL WORLD MULTI CENTRE STUDY OF CPX-351 REVEALS NO DIFFERENCE IN OVERALL SURVIVAL WHEN COMPARED WITH FLAG-IDA AND 3 + 7 IN HIGH RISK AML.19
PB2084: FIRST-LINE TREATMENT IN ADVANCED STAGE FOLICULAR LYMPHOMA: A SINGLE-CENTER EXPERIENCE WITH R-CHOP VS BENDAMUSTINE-RITUXIMAB.19
P1250: EU-SOX11CCND1: A NOVEL IMMUNOCOMPETENT MURINE MODEL OF MANTLE CELL LYMPHOMA19
PB2319: ACQUIRED COAGULOPATHY: FACTOR X DEFICIENCY AT DIAGNOSIS OF MULTIPLE MYELOMA WITHOUT ASSOCIATED AMYLOIDOSIS19
P-016: DEVELOPMENT OF A CLINICAL SEVERITY SCORING SYSTEM FOR INDIAN SICKLE CELL ANAEMIA PATIENTS18
PB2268: IMPACT OF HEMATOLOGICAL DISORDERS ON MORTALITY AND SERIOUS OUTCOMES IN SARS-COV-2 INFECTION: A MULTICENTER COHORT STUDY18
PB2140: ALLOGENEIC STEM CELL TRANSPLANTATION IN RARE T-NHL SUBTYPES: FOCUS ON AITL, MF/SS, HSTCL. A SINGLE BMT-UNIT EXPERIENCE.18
S227: SBNO2 IS A SPECIFIC DEPENDENCY OF STAT3-DRIVEN T-CELL MALIGNANCIES18
P1088: UPDATED DATA FROM A PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN COMBINED WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA18
P-073: SICKLE CELL ANEMIA: MAPPING AND MOLECULAR CHARACTERIZATION OF HEMOGLOBIN MUTATIONS AND THEIR CLINICAL CORRELATION IN TRIBAL AND NON-TRIBAL POPULATIONS OF MADHYA PRADESH.18
PB2002: OBSERVATIONAL PROSPECTIVE STUDY TO INVESTIGATE THE RELATIONSHIP BETWEEN DURATION OF TREATMENT AND RESPONSE IN PATIENTS WITH MULTIPLE MYELOMA OR AL AMYLOIDOSIS: THE DORIANT STUDY (NCT: 0465979817
S174: HIGH LEVEL OF CIRCULATING TUMOUR DNA AT DIAGNOSIS CORRELATES WITH DISEASE SPREADING AND DEFINES MULTIPLE MYELOMA PATIENTS WITH POOR PROGNOSIS17
P761: MONOCYTOSIS IN PRIMARY CARE AND HEMATOLOGICAL MALIGNANCIES17
P668: ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB OR BENDAMUSTINE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: ASCEND RESULTS AT ~4 YEARS OF FOLLOW-UP16
P1175: REAL LIFE OUTCOMES OF RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: A SINGLE CENTRE EXPERIENCE16
5612571 EARLIER PRENATAL DIAGNOSIS OF HEMOGLOBINOPATHIES BY CELOCENTESIS16
COVID-19 AND MYELOMA16
5559749 A MULTICENTER, RETROSPECTIVE STUDY ON REAL-WORLD EXPERIENCE OF PATIENTS WITH SICKLE CELL DISEASE TREATED WITH VOXELOTOR16
PB2233: SYSTEMATIC LITERATURE REVIEW OF HEALTH-RELATED QUALITY OF LIFE BURDEN IN PATIENTS ACROSS THE SPECTRUM OF THALASSEMIA16
PB1937: UTILITY OF STERNAL BONE MARROW CELL MORPHOLOGY EVALUATION FOR DIAGNOSTIC CATEGORIZATION IN PATIENTS WITH ACQUIRED HYPOCELLULAR BONE MARROW FAILURE SYNDROMES16
5613274 “A PICTURE IS OFTEN WORTH MORE THAN MANY WORDS: STREET ART AS EMPOWERMENT FOR SICKLE CELL DISEASE PATIENTS” JACKELINE ELIZABETH MARAN1, MARINA PERDIBON1, ILARIA BAIDO1, MICHEL NKONGNE GYSLENE216
P895: DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D-VD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) ALONE IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF LEPU15
PB1754: TELOMERE LENGTH IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA15
P441: DIFFERENCES IN GENE EXPRESSION PATTERN AND IMMUNOPHENOTYPE OF BONE MARROW MULTIPOTENT MESENCHYMAL STROMAL CELLS IN PATIENTS AT THE ONSET OF ACUTE LEUKEMIA AND AFTER ACHIEVING REMISSION15
P1746: LONG-TERM NON-HODGKIN LYMPHOMA SURVIVORS IN CÔTE D’OR: HEALTH-RELATED QUALITY OF LIFE AND LIVING CONDITIONS.14
PB1897: DISCONTINUATION OF IMATINIB IN PATIENTS FOLLOWED FOR CHRONIC MYELOID LEUKEMIA IN DEEP MOLECULAR RESPONSE14
P1638: EARLY USE OF ELTROMBOPAG IN ADULT PATIENTS WITH ITP WHO ARE REFRACTORY OR RELAPSED AFTER FIRST-LINE CORTICOSTEROID THERAPY – AN AD HOC ANALYSIS OF THE TAPER TRIAL RESULTS14
PB2064: RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS TREATED WITH RADIOTHERAPY14
PB2314: OLIPUDASE ALFA FOR ADULTS WITH ACID SPHINGOMYELINASE DEFICIENCY: IMPROVEMENTS IN CROSSOVER PLACEBO PATIENTS AND FURTHER IMPROVEMENTS IN ORIGINAL OLIPUDASE ALFA PATIENTS AFTER 2 YEARS IN ASCEND14
P342: BASELINE GENE EXPRESSION ANALYSIS OF RELAPSED ACUTE B-LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED WITH INOTUZUMAB OZOGAMICIN14
PB1900: COVID-19 IMPACT ON CHRONIC MYELOID LEUKEMIA PATIENTS14
PB2238: ΒETA-THALASSEMIA INTERMEDIA: INTERACTION OF ΑLPHA-GLOBIN GENE TRIPLICATION WITH ΒETA-THALASSEMIA HETEROZYGOUS IN SPAIN14
PB2275: IMPACT OF EARLY FEVER ONSET AND NOVEL ANTIBIOTICS PROLONGED FEBRILE NEUTROPENIA OUTCOME FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION. SINGLE CENTER 10-YEAR RETROSPECTIVE STUDY14
P861: SIALOFUCOSYLATED STRUCTURES ENABLE PLATELET BINDING TO MYELOMA CELLS CONFERRING PROTECTION FROM NK-MEDIATED CYTOTOXICITY14
PB2025: MANAGEMENT AND PATIENT ESTIMATION OF AMYLOID LIGHT-CHAIN (AL) AMYLOIDOSIS IN PORTUGAL: RESULTS FROM A PHYSICIANS’ SURVEY13
P516: ADULT LANGERHANS CELL HISTIOCYTOSIS WITH THYROID GLAND INVOLVEMENT: CLINICAL PRESENTATION, GENOMIC ANALYSIS AND OUTCOME13
PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)13
P-040: RED BLOOD CELLS ADHESION AND OCCLUSION INDEX IN A PATIENT WITH SICKLE CELL DISEASE PRIOR AND POST HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)13
P1241: A NOVEL CEREBLON-BINDING MOLECULAR GLUE, SP-3164, SHOWS PRECLINICAL ACTIVITY IN NON-HODGKIN LYMPHOMAS13
P869: PRODUCTION BY GUT MICROBIOTA AS PROGNOSTIC BIOMARKER IN MM13
P1600: ANTIGENS OF THE DUFFY BLOOD GROUP SYSTEM AND RISK OF COVID-19 INFECTION13
P372: DISMAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER FAILURE OF BOTH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB13
P652: MEASURING MINIMAL RESIDUAL DISEASE BEYOND 10-4 THROUGH IGHV LEADER-BASED NEXT GENERATION SEQUENCING IMPROVES PROGNOSTIC STRATIFICATION IN CHRONIC LYMPHOCYTIC LEUKEMIA13
S224: HIGH COMPLETE RESPONSE RATE WITH TNB-486, A NOVEL CD19XCD3 T-CELL ENGAGER, IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM AN ONGOING PHASE 1 STUDY13
The EHA Research Roadmap: Hematopoietic Stem Cells and Allotransplantation13
PB2067: THE REALM STUDY PROTOCOL: A MULTICENTER, NON-INTERVENTIONAL, RETROSPECTIVE STUDY TO DESCRIBE THE TREATMENT PATHWAYS, OUTCOMES, AND RESOURCE USE IN PATIENTS WITH CD30+ LYMPHOMA FROM CHINA.13
P1043: OUTCOME OF PATIENTS WITH PREFIBROTIC MYELOFIBROSIS FROM A LARGE ACADEMIC CENTER13
PB1871: PROGNOSTIC SIGNIFICANCE OF THE NOTCH1 GENE MUTATION AND OTHER LABORATORY FACTORS IN CHRONIC LYMPHOCYTIC LEUKEMIA13
P612: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)-DERIVED T-CELLS HAVE DISTURBED FATTY ACID METABOLISM, POSSIBLY CONTRIBUTING TO T-CELL DYSFUNCTION13
P723: LOSS OF THE NK MOTIF AND ANKYRIN REPEAT DOMAIN 1 (KANK1) LEADS TO LYMPHOID COMPARTMENT DYSREGUATION IN MICE13
PB2127: NO IMPACT OF STATIN USE ON RESPONSE AND SURVIVAL RATES IN NEWLY DIAGNOSED DLBCL PATIENTS TREATED WITH R-DA-EPOCH12
PB2203: AGEING OF LONG-TERM ALLOGENEIC HEMATOPOIETIC CELLS RECIPIENTS COMPARED TO THEIR DONORS12
P1496: OPERATOR-INDEPENDENT, FLUORESCENCE-BASED QUANTIFICATION OF POCKED RED CELLS CORRELATES WITH SPLEEN SIZE AND FUNCTION IN SICKLE CELL DISEASE12
P815: PHARMACOKINETIC AND PHARMACODYNAMIC SIMILARITY OF ABP 959 AND ECULIZUMAB REFERENCE PRODUCT: UNBOUND ECULIZUMAB AND CH50 FROM THE RANDOMIZED, DOUBLE-BLIND, SINGLE-DOSE STUDY IN HEALTHY VOLUNTEERS12
P463: RE-PURPOSING OF GENE SIGNATURES IN AML UNCOVERS NOVEL ENERGETICS-ASSOCIATED MOLECULAR SUBTYPES12
P788: FACTORS DRIVING TREATMENT DECISION IN PATIENTS WITH INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROME (MDS): A RETROSPECTIVE ANALYSIS FROM THE GRUPO ESPAÑOL DE SÍNDROMES MIELODISPLÁSICOS SPANISH MDS RE12
PB2063: CHARACTERISTICS AND THERAPEUTIC RESULTS OF PATIENTS WITH REFRACTORY/RELAPSED HODGKIN LYMPHOMA IN A TUNISIAN CENTER12
P-070: PLANNING IMPLEMENATION OF PEDIATRIC-TO-ADULT CARE TRANSITION IN SICKLE CELL DISEASE IN BRAZIL12
PB1852: AZACITIDINE COMBINED WITH HAG REGIMEN FOR ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA:PRIMARY ANALYSIS OF A RETROSPECTIVE COHORT12
P634: MHC-BASED LARGE-SCALE SCREENING FOR ANTI-TUMOR T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA REVEALS CD8+ T CELLS WITH SPECIFICITY AGAINST THE CLONOTYPIC B-CELL RECEPTOR IMMUNOGLOBULIN12
P531: MIDOSTAURIN PLUS 7 + 3 OR QUIZARTINIB PLUS 7 + 3 IN FLT3-ITD MUTATED AML11
P706: RESISTANCE TO HYPOMETHYLATING AGENTS (HMA) IN HIGH-RISKMYELODYSPLASTIC SYNDROME (HR-MDS): THE ROLE OF THE ADENOSINEDEAMINASE ACTING ON RNA 1 (ADAR1) ENZYME11
Choroidal and Ocular Adnexal Lymphoma Extension From Systemic Mantle Cell Lymphoma: A Case Report11
PB1772: HIGH SLIT2 LEVELS ARE ASSOCIATED WITH GMP LIKE AML AND TREATMENT WITH RECOMBINANT SLIT2 INHIBITS LEUKEMOGENESIS11
P743: CLINICAL OUTCOMES OF PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS11
S241: ITACONATE INHIBITS TH1 DIFFERENTIATION AND ACUTE GRAFT-VERSUS-HOST DISEASE VIA NRF211
P489: PROGNOSTIC IMPACT OF “MULTI-HIT” VERSUS “SINGLE-HIT” TP53 MUTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: RESULTS FROM THE CONSORTIUM ON MYELOID MALIGNANCIES AND NEOPLASTIC DISEASES (COMMAND)11
P687: EARLY RESULTS OF A PHASE II STUDY EVALUATING THE ADDITION OF ASCIMINIB TO ERADICATE MINIMAL RESIDUAL DISEASE IN CHRONIC MYELOID LEUKEMIA11
P500: SUPERIOR OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AMONG PATIENTS ≥ 60 YEARS TREATED WITH CLADRIBINE, LOW DOSE CYTARABINE PLUS VENETOCLAX FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA11
P409: BCL-2/BCL-XL INHIBITION INDUCES APOPTOSIS AND CIRCUMVENTS VENETOCLAX RESISTANCE IN TP53-MUTATED ACUTE MYELOID LEUKEMIA11
P372: CMV REACTIVATIONS/INFECTIONS IN PH+ ALL PATIENTS TREATED WITH DASATINIB WITH OR WITHOUT BLINATUMOMAB. A RETROSPECTIVE MULTICENTER CAMPUS ALL STUDY11
P1281: REFRACTORY PATIENTS WITH FAVORABLE/INTERMEDIATE-RISK AML BENEFIT FROM AZACYTIDINE MAINTENANCE THERAPY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION11
P927: ACTUAL USAGE OF CURRENT SYSTEMIC TREATMENTS AND INFLUENCE OF KEY DRIVERS FOR MULTIPLE MYELOMA IN THE FIRST 2 LINES OF THERAPY. DATA FROM REAL-WORLD STUDY IN EU5 COUNTRIES.11
P1635: DETERMINATION OF THE EFFECTIVE CONCENTRATION OF TRANEXAMIC ACID NEUTRALIZING IN AN IN VITRO UROKINASE INDUCED HYPERFIBRINOLYTIC MODEL USING A GLOBAL FIBRINOLYTIC CAPACITY ASSAY10
P1262: GILTERITINIB MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH FLT3–INTERNAL TANDEM DUPLICATION MUTATION10
P1380: THE COMPOSITION OF INFUSED CD19-CAR-T PRODUCT IMPACTS ON EFFICACY10
PB2443: APPLICABILITY OF SHORT TANDEM REPEAT (STR) IN LEUKEMIA PATIENTS RECEIVED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE ERA OF MINIMAL RESIDUAL DISEASE (MRD)10
PB2672: EXPLORING UNMET NEEDS OF PATIENTS WITH MYELODYSPLASTIC NEOPLASMS AND CAREGIVERS IN A NATIONAL ITALIAN SURVEY10
P1586: COMPARISON OF FREQUENCY OF TRANSFUSION RELATED COMPLICATIONS IN THALASSEMIC AND NON-THALASSEMIC PATIENTS RECEIVING NON LEUKODEPLETED RED CELL CONCENTRATE.10
PB1727: EVALUATION OF POST-TREATMENT SECONDARY CANCERS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH MODIFIED ST. JUDE TOTAL XIII AND TOTAL XV PROTOCOLS.10
PB2501: INSIGHT-1: A PHASE I FIRST-IN-HUMAN TCR TRIAL OF GENETICALLY MODIFIED T-CELLS TARGETING TDT IN CHILDREN AND ADULTS WITH T- AND B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (TRIAL-IN-PROGRESS)10
PB2085: EPIDEMIOLOGICAL DESCRIPTION AND PROGNOSIS FEATURES OF MULTIPLE MYELOMA IN A TUNISIAN HAEMATOLOGY CENTER10
P993: INCREASED STAT5B LEVELS IN MYELOPROLIFERATIVE NEOPLASMS LEAD TO ENHANCED MEGAKARYOCYTIC DIFFERENTIATION CORRELATING WITH THROMBOSIS10
P480: DNMT AND HDAC INHIBITION INDUCES IMMUNOGENIC NEOANTIGENS FROM HUMAN ENDOGENOUS RETROVIRAL ELEMENT-DERIVED TRANSCRIPTS10
P602: SINGLE-CELL RNA-SEQUENCING ENABLES TRACKING AND CHARACTERIZATION OF RARE CLL CELLS WITH THE POTENTIAL TO CAUSE REFRACTORINESS.10
P1571: PREVENTION OF COVID19 IN PATIENTS WITH HEMOBLASTOSIS. OWN CLINICAL EXPERIENCE10
P1584: PREVELANCE OF ABO DISCPRENACIES AND ITS CLASSIFACTION IN BLOOD DONORS AT REGIONAL BLOOD CENTRE, KARACHI.10
PB2148: IMPACT OF OBESITY IN THE CLINICAL OF MULTIPLE MYELOMA PATIENTS: A REPORT FROM MMRF DATASET10
PB2174: DISSECTING THE MECHANISM OF INTERFERON ALFA (IFNΑ) RESPONSE IN MYELOPROLIFERATIVE NEOPLASM AND IDENTIFICATION OF PREDICTORS OF RESPONSE10
PB2561: DEVELOPMENT OF COLD AGGLUTININ AUTOIMMUNE HEMOLYTIC ANEMIA DURING TREATMENT FOR PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA: A CASE REPORT.10
P1672: OCCUPATIONAL INTEGRATION OF ADULTS WITH SEVERE HAEMOPHILIA (INTHEMO): A STUDY BASED ON THE FRANCECOAG REGISTRY10
P987: IRAK1 AND JAK2 DUAL INHIBITION WITH PACRITINIB PREVENTS MYELOFIBROSIS-LIKE PHENOTYPE IN AN INFLAMMATION-DRIVEN MURINE MODEL10
P702: APPLICATION OF NEXT GENERATION SEQUENCING (NGS) FOR MINIMAL RESIDUAL DISEASE (MRD) AND CHIMERISM MONITORING IN MYELODYSPLASTIC SYNDROME (MDS) AFTER ALLOGENIC STEM CELL TRANSPLANTATION (ASCT)9
PB2203: INCIDENCE AND PREVALENCE OF MYELOFIBROSIS IN GERMANY: A RETROSPECTIVE CLAIMS DATA ANALYSIS9
PB1784: CLADRIBINE SYNERGIZES THE EFFECT OF VENETOCLAX ON CELL PROLIFERATION ARREST AND APOPTOSIS BY TARGETING DNA-PKCS/C-MYC SIGNALING IN ACUTE MYELOID LEUKEMIA9
P1453: ORTHOTOPIC LIVER TRANSPLANT IN SICILIAN HEMOGLOBINOPHATIES PATIENTS9
P404: IMMUNOGLOBULIN GENE REARRANGEMENT IN KOREAN PATIENTS WITH B-LYMPHOBLASTIC LEUKEMIA – AN IMMUNOPHENOTYPE AND REPERTOIRE ANALYSIS9
PB2163: BORTEZOMIB - CYCLOPHOSPHAMIDE – DEXAMETHASONE (VCD) REGIMEN IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) - EXPERIENCE FROM A RESOURCE CONSTRAINT SETTING IN SOUTH INDIA9
P1147: FEASIBILITY AND OUTCOME AFTER DOSE REDUCTION OF IMMUNOCHEMOTHERAPY IN YOUNG ADULTS WITH BURKITT LYMPHOMA AND LEUKEMIA. RESULTS OF THE BURKIMAB14 TRIAL9
PB2525: A FOUR YEARS’ EXPERIENCE OF UNIVERSAL NEWBORN SCREENING FOR HAEMOGLOBIN DISORDERS IN UDINE, FVG, NORTHERN ITALY9
P1463: HEALTHCARE RESOURCE USE, ECONOMIC BURDEN AND IN-PATIENT MORTALITY IN PATIENTS WITH ALPHA- AND BETA-THALASSEMIA COMPARED TO MATCHED CONTROLS IN THE REAL-WORLD SETTING9
P1671: CARFILZOMIB-DEXAMETHASONE MAINTENANCE HAMPERS RECOVERY AFTER SALVAGE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA9
PB2390: STUDY OF GENETIC ALTERATIONS USING A CUSTOM LYMPHOID TARGETED NGS PANEL IN PATIENTS WITH FOLLICULAR LYMPHOMA: A PILOT STUDY9
P1093: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF ZANUBRUTINIB (ZANU) VERSUS IBRUTINIB (IBRU) IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL)9
P1017: REDUCTIONS IN INDOLENT SYSTEMIC MASTOCYTOSIS BIOMARKER BURDEN WITH AVAPRITINIB IN THE REGISTRATIONAL, DOUBLE-BLIND PLACEBO-CONTROLLED PIONEER TRIAL9
P529: THE EFFECT OF AGE AND TREATMENT ON THE PREDICTIVE VALUE OF MEASURABLE RESIDUAL DISEASE: IMPLICATIONS FOR THE CLINICAL MANAGEMENT OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA9
PB2193: JAK2 V617F MUTATION BURDEN DETECTION AND RELATIONSHIP WITH LABORATORY CHARACTERISTICS IN MYELOPROLIFERATIVE NEOPLASMS9
P899: HOVON 104; LONG TERM FOLLOW-UP OF AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER BORTEZOMIB INDUCTION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS8
P1033: JAKTINIB IN PATIENTS WITH MYELOFIBROSIS WHO WERE REFRACTORY OR RELAPSED TO RUXOLITINIB: A SINGLE-ARM, OPEN-LABEL, MULTICENTER, PHASE 2 STUDY8
PB2226: HIGH RISK LANGERHANS CELL HISTIOCYTOSIS (LCH) IN CHILDREN: THE ROLE OF CLADRIBINE SALVAGE IN IMPROVING THE OUTCOME. A SINGLE CENTER EXPERIENCE8
PB2083: IN-VITRO EVALUATION OF LENALIDOMIDE ENANTIOMERS AGAINST HUMAN MULTIPLE MYELOMA CELL LINE8
P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA8
PB2046: CHANGINGS IN GENETIC DEFINITION AND MANAGEMENT OF ACQUIRED APLASTIC ANEMIA: A SINGLE CENTER EXPERIENCE8
P1445: THE IMPACT OF ILLNESS PERCEPTION AND STIGMA ON PATIENT-REPORTED OUTCOMES IN SICKLE CELL DISEASE8
S304: WHAT IS A MASSIVE TRANSFUSION? A SCOPING REVIEW TO INFORM AN INTERNATIONAL CONSENSUS DEFINITION8
Prediction of the Clinical Course of Immune Thrombocytopenia in Children by Platelet Kinetics8
PB1815: ADDITIONAL СYTOGENETIC ABNORMALITIES IN ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)8
P780: G-CSF THERAPY IN EUROPEAN PATIENTS WITH SHWACHMAN-DIAMOND SYNDROME8
P1223: IMAGING MASS CYTOMETRY REVEALS A HIGHLY HETEROGENOUS CELL MAKEUP AND SPATIAL CONTEXT OF THE FOLLICULAR LYMPHOMA TUMOR MICROENVIRONMENT8
B07 HIGH EXPRESSION OF NUCLEAR CEREBLON IS ASSOCIATED WITH LONGER SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IMIDS8
P1683: THE EORTC QLQ-HL27: EORTC PROSPECTIVE INTERNATIONAL VALIDATION OF A DISEASE-SPECIFIC QUESTIONNAIRE FOR ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HODGKIN LYMPHOMA8
PB2381: EFFICACY ANALYSIS OF BRUTON’S TYROSINE KINASE INHIBITOR COMBINED REGIMEN IN THE TREATMENT OF ELDERLY PATIENTS WITH RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA8
PB1853: OUTCOMES REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA WITH EXTRAMEDULLARY MANIFESTATIONS AFTER GEMTUZUMAB OZOGAMICIN THERAPY8
P885: SOLITARY PLASMACYTOMA: SINGLE INSTITUTION EXPERIENCE AND SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL OUTCOMES8
Why Do We Diagnose Monoclonal B-cell Lymphocytosis? Five Questions7
PB2356: OUTCOMES OF PATIENTS WITH PRIMARY CNS LYMPHOMA (PCNSL) WHO UNDERWENT TREATMENT WITH DEANGELIS, MATRIX, AND PRIMAIN PROTOCOL.: A RETROSPECTIVE SINGLE-CENTER STUDY7
P805: ALEMTUZUMAB IN RELAPSED SEVERE APLASTIC ANEMIA: LONG-TERM RESULTS OF A PHASE II STUDY7
P908: IDENTIFICATION OF CYTOKINES ASSOCIATED WITH RESPONSE AND CYTOKINE RELEASE SYNDROME – ANALYSIS OF MAGNETISMM-3 COHORT A7
PB2421: EPSTEIN-BARR VIRUS-ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE: RESULTS OF A DELPHI STUDY IN SPAIN.7
P1681: RACIAL DIFFERENCES IN DETERMINANTS OF TREATMENT DECISION-MAKING AMONG PATIENTS WITH MULTIPLE MYELOMA7
Antibiotic‐associated neutropenia is marked by the depletion of intestinal Lachnospiraceae and associated metabolites in pediatric patients7
P1677: DEFINING KEY QUALITY OF LIFE METRICS IN ACUTE MYELOID LEUKAEMIA AND HIGH RISK MYELODYSPLASTIC SYNDROME PATIENTS ENROLLED IN LARGE-SCALE UK NCRI AML TRIALS7
PB2350: SAFETY AND EFFICACY OF HYPODERMOCLYSIS IN PATIENTS WITH HEMATOLOGICAL CANCERS7
P1000: JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML) INHIBITS T CELL PROLIFERATION VIA THE ECTONUCLEOTIDASE CD39 AND THE PURINERGIC NETWORK7
P1506: TECLISTAMAB REDUCES POLYCLONAL IMMUNOGLOBULIN LEVELS AND IMPAIRS VACCINATION RESPONSES IN HEAVILY PRETREATED MM PATIENTS7
P533: A FULLY AUTOMATED SUPERVISED AI-BASED CELL CLASSIFIER TO ACCURATELY FLAG PATHOLOGICAL SIGNATURE CELLS IN 28,285 REAL-WORLD BLOOD SMEARS7
P1298: THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN-BASED CONDITIONING REGIMEN FOR ALLOGENEIC-HSCT IN REFRACTORY/RELAPSED OR PERSISTENT MRD POSITIVITY AML PATIENTS7
P772: LONG-TERM RAVULIZUMAB TREATMENT IN COMPLEMENT INHIBITOR-EXPERIENCED PATIENTS WITH PNH PROVIDES DURABLE CONTROL OF INTRAVASCULAR HEMOLYSIS WITH LOW INCIDENCE OF MAJOR ADVERSE VASCULAR EVENTS AND 7
Issue Information7
PB2449: EFFECT OF MOBILIZATION METHODS ON CD34+ AND TOTAL NUCLEATED CELL COUNT AND THEIR RELATION WITH ENGRAFTMENT IN AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION7
AP-1 Transcription Factor Complex Members FOSB and FOS are Linked With CNS Infiltration and Inferior Prognosis in Childhood T-ALL7
PB2350: HEMATOLOGIC MALIGNANCIES AND AUTO-IMMUNITY: A CASE SERIES OF 21 PATIENTS7
P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS7
PB2107: EVOLUTION OF SELECTION CRITERIA FOR PHASE 3 CLINICAL TRIALS IN MULTIPLE MYELOMA.7
P1379: DEVELOPMENT OF A GENE THERAPY CELL DEATH-INDUCING SYSTEM REGULATED BY MICRORNAS FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA.7
S140: IBRUTINIB SENSITIZES CLL CELLS TO VENETOCLAX BY INTERRUPTING TLR9-INDUCED CD40 UPREGULATION AND PROTEIN TRANSLATION7
Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial6
Efficacy of anti‐PD1 therapy in extranodal NK/T cell lymphoma: A matched cohort analysis from the LYSA6
Prognostic risk and survival of asymptomatic IgM monoclonal gammopathy: Results from a Spanish Multicenter Registry6
S113: NATIONAL PEGASPARGASE-MODIFIED RISK-ORIENTED PROGRAM FOR PHILADELPHIA-NEGATIVE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA (PH− ALL/LL). GIMEMA LAL 1913 FINAL RESULTS.6
P976: BENDAMUSTINE-POMALIDOMIDE-DEXAMETHASONE (BPD) FOR RELAPSED AND/OR REFRACTOR MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE6
P937: PRECLINICAL DISCOVERY AND EARLY FINDINGS FROM THE PHASE 1, DOSE-ESCALATION STUDY OF WVT078, A BCMA-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH R/R MULTIPLE MYELOMA6
Issue Information6
P876: ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND DARATUMUMAB OR BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA—FINAL EFFICACY AND SAFETY RESULTS6
Progressive Multifocal Leukoencephalopathy in B-CLL Successfully Treated With Venetoclax and Pembrolizumab6
Implementation science in hemato‐oncology molecular diagnostics in France via the Groupe des Biologistes Moléculaire des Hémopathies Malignes (GBMHM)6
6
P641: RETREATMENT WITH VENETOCLAX AFTER VENETOCLAX, OBINUTUZUMAB +/- IBRUTINIB: POOLED ANALYSIS OF 13 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN GCLLSG TRIALS6
Issue Information6
First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial6
Temporal Trends in the Incidence of Hemophagocytic Lymphohistiocytosis: A Nationwide Cohort Study From England 2003–20186
PB2267: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-1)6
Clonal Hematopoiesis and Epigenetic Age Acceleration in Elderly Danish Twins6
PB1740: THE COMBINATION OF PONATINIB PLUS CHEMOTHERAPY UPFRONT ACHIEVES DURABLE COMPLETE MOLECULAR REMISSIONS IN ADULTS PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMI6
PB1747: OUTCOME OF CHILDHOOD ALLTREATED WITH ALL BFM IC 2009 PROTOCOL6
Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall Survival6
P1471: SUSTAINED EFFICACY OF SUTIMLIMAB, A COMPLEMENT C1S INHIBITOR, IN PATIENTS WITH COLD AGGLUTININ DISEASE: RESULTS FROM PART B OF THE PHASE 3 CADENZA STUDY6
Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments6
Delving deeper into the pathogenesis and genomics of posttransplant diffuse large B‐cell lymphoma6
Annual Sickle Cell & Thalassaemia Conference (ASCAT) ‐ October 20236
P629: THE CLL TREATMENT INFECTION MODEL – CLINICAL PROSPECTIVE VALIDATION AS PART OF THE PREVENT-ACALL TRIAL6
S162: SOMATIC GENETIC LANDSCAPE IN GATA2 DEFICIENCY PATIENTS6
Bone marrow niches for hematopoietic stem cells6
Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria6
PB2317: COINHERITANCE OF COMBINED FACTOR VII AND FACTOR XIII DEFICIENCY IS ASSOCIATED WITH A MILD BLEEDING PHENOTYPE IN PATIENT WITH NON-TRANSFUSION DEPENDENT THALASSEMIA6
P1429: MULTIPLEX DELETION OF MYELOID ANTIGENS CD33 AND CLL-1 BY CRISPR/CAS9 IN HUMAN HEMATOPOIETIC STEM CELLS HIGHLIGHTS THE POTENTIAL OF NEXT-GENERATION TRANSPLANTS FOR AML TREATMENT.6
P1290: UPFRONT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION CAN PROVIDE SURVIVAL BENEFIT VERSUS HYPOMETHYLATING AGENT IN MYELODYSPLASTIC SYNDROME WITH INCREASED BLASTS I (MDS-IBI)6
PB2154: THE IMPACT OF DISEASE SEVERITY ON THE CLINICAL AND ECONOMIC BURDEN OF AL AMYLOIDOSIS6
P353: FORTY MONTHS UPDATE OF THE GIMEMA LAL2116 (D-ALBA) PROTOCOL AND ANCILLARY LAL2217 STUDY FOR NEWLY DIAGNOSED ADULT PH+ ALL6
S167: PREDICTION OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION USING INDIVIDUALIZED MEASURABLE RESIDUAL DISEASE MARKERS; THE PROSPECTIVE NORDIC STUDY NMDSG14B6
T100: Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Gro6
Harnessing the Gut Microbiota to Potentiate the Efficacy of CAR T Cell Therapy6
P379: PONATINIB AND BLINATUMOMAB IN RELAPSED/REFRACTORY PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA OR CHRONIC MYELOID LEUKEMIA IN LYMPHOID BLAST PHASE: SUBGROUP ANALYSIS FROM A PHASE II TRIAL6
S104: DIFFERENTIAL TARGET PROFILES AND EFFICACY OF ADCLEC.SYN1 AND CD33-CARS IN HUMANIZED AML MODELS6
P614: NOVEL SPLICE-SITE MUTATION IN PLCG2 ASSOCIATED WITH RESISTANCE TO BTK INHIBITORS5
PB2370: EXTRANODAL NATURAL KILLER (NK)/T-CELL LYMPHOMA, NASAL-TYPE: ABOUT 11 CASES5
P089: Pembrolizumab in Pediatric and Young Adults Patients With Newly Diagnosed Classical Hodgkin Lymphoma and Slow Early Responders to Frontline Chemotherapy: The Phase 2 KEYNOTE-667 Study5
PB2522: LIPID PROFILE AND CARDIAC FUNCTIONS IN EGYPTIAN SICKLE CELL DISEASE PATIENTS: A SINGLE CENTER STUDY5
Correction Notice – Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study5
P1744: ACCURACY OF PREDICTING LONG-TERM SURVIVAL OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPIES IN LARGE B-CELL LYMPHOMA (LBCL)5
P596: CLINICAL IMPACT OF TP53 DISRUPTION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH A BCR INHIBITOR. A CAMPUS CLL EXPERIENCE5
P-035: RED BLOOD CELL ALLOIMMUNIZATION IN SICKLE CELL DISEASE PATIENTS IN THE DEMOCRATIC REPUBLIC OF THE CONGO5
P1517: HUMORAL AND CELLULAR IMMUNE RESPONSES TO SARS-COV-2 NATURAL INFECTION OR VACCINATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A STUDY BY ERIC, THE EUROPEAN RESEARCH INITIATIVE ON CL5
P526: REAL-WORLD COMPARISON OF DIFFERENT TREATMENT MODALITIES FOR FAVORABLE RISK ACUTE MYELOID LEUKEMIA: STANDARD DOSE ANTHRACYCLINE VS HIGH DOSE ANTHRACYCLINE VS ADDITION OF GEMTUZUMAB OZOGAMICIN5
P1105: NEUROLOGIC INVOLVEMENT IN ADULTS WITH ROSAI-DORFMAN DISEASE: CLINICAL PRESENTATION AND OUTCOMES5
5613327 KNOCK-DOWN OF AUTOPHAGY-RELATED GENE 5 (ATG5) EXPRESSION IN THALASSEMIC CD34+ CELLS LEADS TO AMELIORATION OF ERYTHROPOIESIS5
PB1932: RETROSPECTIVE STUDY OF BURDEN OF INFECTION IN PATIENTS WITH AND WITHOUT SECONDARY IMMUNODEFICIENCY DISEASE FOLLOWING DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKAEMIA5
PB2172: IRON OXIDE NANOPARTICLES INHIBIT DIFFUSE LARGE B LYMPHOMA CELL SURVIVAL AND INVASION5
S271: BONE MARROW TFR2 DELETION IMPROVES THE THERAPEUTIC EFFECT OF ACTIVIN LIGAND TRAP RAP-536 IN Β-THALASSEMIC MICE5
FROM BENIGN TO MALIGNANT DISEASE5
High Incidence of Herpes Zoster in Patients Using Ruxolitinib for Myeloproliferative Neoplasms: Need for Prophylaxis5
P1345: IMMUNE RECONSTITUTION AFTER BMT FOR NON-MALIGNANT HEMATOLOGICAL CONDITIONS FOR RELATED, UNRELATED AND HAPLOIDENTICAL DONORS. A STUDY IN THE PEDIATRIC DEPARTMENT AT ST MARY’S HOSPITAL BETWEEN 205
Prognostic Stratification of Diffuse Large B-cell Lymphoma Using Clinico-genomic Models: Validation and Improvement of the LymForest-25 Model5
P479: TREATMENT IS SHAPING CLONAL EVOLUTION AND RESISTANCE PATTERNS IN MURINE KMT2A-REARRANGED LEUKEMIA WITH SUBCLONAL FLT3N676K5
PB2149: MINIMAL RESIDUAL DISEASE (MRD) DETECTION TRENDING AS A PRIMARY ENDPOINT IN CERBA RESEARCH MULTIPLE MYELOMA (MM) TRIALS5
P1398: INSIGHT INTO ACUTE MYELOID LEUKEMIA INDUCED MSC SECRETOME TO REROUTE THE COURSE OF LEUKEMIA BONE MARROW NICHE5
P736: BCOR MUTATION REGULATES MYELODYSPLASTIC SYNDROMES PROGRESSION THROUGH REPRESSING AUTOPHAGY FLUX MEDIATED BY HDAC6 ACTIVATION5
PB2026: ROLE OF MOLECULAR PROFILING IN MYELODYSPLASTIC SYNDROME IN REAL-WORLD - A NEW APPROACH IN MYELODYSPLASTIC SYNDROME’S RISK STRATIFICATION?5
PB1847: ACUTE MYELOID LEUKEMIA – IS IT MORE BESIDES GENETIC ABNORMALITIES?5
PB2169: METHYLATION OF P53-RESPONSIVE ONCOSUPPRESSIVE MICRORNA GENES IN DIFFUSE LARGE B-CELL LYMPHOMA TUMOR TISSUE5
P-032: INTEGRATIVE DIAGNOSIS OF SICKLE CELL DISEASE PATIENTS FOR PERSONALIZED MEDICINE5
PB1905: FEASIBILITY OF TREATMENT DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA IN CLINICAL PRACTICE: RESULTS FROM A SERIES OF 19 PATIENTS5
P1227: POLATUZUMAB VEDOTIN, RITUXIMAB, AND BENDAMUSTINE COMBINATION IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-WORLD DATA FROM TURKEY5
0.056211948394775